Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.23 billion. The enterprise value is $4.16 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 48.18 million shares outstanding. The number of shares has decreased by -4.63% in one year.
| Current Share Class | 48.18M |
| Shares Outstanding | 48.18M |
| Shares Change (YoY) | -4.63% |
| Shares Change (QoQ) | -1.42% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 113.20% |
| Float | 47.60M |
Valuation Ratios
The trailing PE ratio is 19.54 and the forward PE ratio is 13.00. Haemonetics's PEG ratio is 1.07.
| PE Ratio | 19.54 |
| Forward PE | 13.00 |
| PS Ratio | 2.47 |
| Forward PS | 2.39 |
| PB Ratio | 3.69 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.09 |
| P/OCF Ratio | 11.19 |
| PEG Ratio | 1.07 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 11.34, with an EV/FCF ratio of 18.13.
| EV / Earnings | 24.74 |
| EV / Sales | 3.13 |
| EV / EBITDA | 11.34 |
| EV / EBIT | 16.04 |
| EV / FCF | 18.13 |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 1.44.
| Current Ratio | 1.64 |
| Quick Ratio | 0.92 |
| Debt / Equity | 1.44 |
| Debt / EBITDA | 3.23 |
| Debt / FCF | 5.34 |
| Interest Coverage | 5.79 |
Financial Efficiency
Return on equity (ROE) is 19.47% and return on invested capital (ROIC) is 7.60%.
| Return on Equity (ROE) | 19.47% |
| Return on Assets (ROA) | 6.53% |
| Return on Invested Capital (ROIC) | 7.60% |
| Return on Capital Employed (ROCE) | 13.70% |
| Revenue Per Employee | $439,249 |
| Profits Per Employee | $55,637 |
| Employee Count | 3,023 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, Haemonetics has paid $48.92 million in taxes.
| Income Tax | 48.92M |
| Effective Tax Rate | 22.53% |
Stock Price Statistics
The stock price has decreased by -10.50% in the last 52 weeks. The beta is 0.36, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -10.50% |
| 50-Day Moving Average | 51.24 |
| 200-Day Moving Average | 62.59 |
| Relative Strength Index (RSI) | 85.19 |
| Average Volume (20 Days) | 803,465 |
Short Selling Information
The latest short interest is 3.34 million, so 6.93% of the outstanding shares have been sold short.
| Short Interest | 3.34M |
| Short Previous Month | 3.39M |
| Short % of Shares Out | 6.93% |
| Short % of Float | 7.01% |
| Short Ratio (days to cover) | 3.28 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.33 billion and earned $168.19 million in profits. Earnings per share was $3.44.
| Revenue | 1.33B |
| Gross Profit | 795.04M |
| Operating Income | 259.38M |
| Pretax Income | 217.11M |
| Net Income | 168.19M |
| EBITDA | 366.92M |
| EBIT | 259.38M |
| Earnings Per Share (EPS) | $3.44 |
Full Income StatementBalance Sheet
The company has $296.43 million in cash and $1.22 billion in debt, giving a net cash position of -$928.30 million or -$19.27 per share.
| Cash & Cash Equivalents | 296.43M |
| Total Debt | 1.22B |
| Net Cash | -928.30M |
| Net Cash Per Share | -$19.27 |
| Equity (Book Value) | 849.17M |
| Book Value Per Share | 18.17 |
| Working Capital | 351.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $289.04 million and capital expenditures -$59.57 million, giving a free cash flow of $229.47 million.
| Operating Cash Flow | 289.04M |
| Capital Expenditures | -59.57M |
| Free Cash Flow | 229.47M |
| FCF Per Share | $4.76 |
Full Cash Flow StatementMargins
Gross margin is 59.87%, with operating and profit margins of 19.53% and 12.67%.
| Gross Margin | 59.87% |
| Operating Margin | 19.53% |
| Pretax Margin | 16.35% |
| Profit Margin | 12.67% |
| EBITDA Margin | 27.63% |
| EBIT Margin | 19.53% |
| FCF Margin | 17.28% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.63% |
| Shareholder Yield | 4.63% |
| Earnings Yield | 5.20% |
| FCF Yield | 7.10% |
Dividend DetailsAnalyst Forecast
The average price target for Haemonetics is $79.22, which is 18.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $79.22 |
| Price Target Difference | 18.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |
